<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865030</url>
  </required_header>
  <id_info>
    <org_study_id>0019-19</org_study_id>
    <nct_id>NCT03865030</nct_id>
  </id_info>
  <brief_title>The Inner Ear Function in Psoriatic Patients</brief_title>
  <acronym>MP</acronym>
  <official_title>Audiovestibular Manifestations in Patients With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis in a systemic disease that effects many systems of the body. few studies examined&#xD;
      the hearing function of these patients but the results were inconclusive. No study, however,&#xD;
      investigated the vestibular function of psoriatic patients.&#xD;
&#xD;
      In a prospective study, the investigators will compare audiovestibular function between&#xD;
      psoriatic patients and healthy volunteers. .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Whether psoriatic patients have higher risk for developing inner ear dysfunction (hearing&#xD;
      loss and dizziness) is an important issue that needs to be elucidated. Awareness to the&#xD;
      elevated risk (if there is any) of inner ear impairment, early detection and treatment of the&#xD;
      condition may reduce the morbidities resulting from undiagnosed audiovestibular impairment.&#xD;
&#xD;
      In a prospective study the investigators will examine the inner ear function (vestibular and&#xD;
      auditory) of psoriatic patients and compare it to an healthy, young control group.&#xD;
&#xD;
      The study will include 2 groups of participants: psoriatic patients and healthy volunteers.&#xD;
      psoriatic patients are recruited from the dermatology clinic while the healthy volunteers are&#xD;
      members of the hospital staff.&#xD;
&#xD;
      The participants will undergo 2 sets of examinations:&#xD;
&#xD;
        1. auditory function examination: hearing test (that includes pure tone audiometry, speech&#xD;
           audiometry and discrimination level), tympanometry and otoacoustic emissions.&#xD;
&#xD;
        2. vestibular function examination:&#xD;
&#xD;
             -  Video head impulse test: a ten-minute, non- invasive test that includes a computer&#xD;
                and a set of goggles worn by the participant. The participants is sitting in front&#xD;
                of a wall while wearing the goggles, the investigator moves the participant's head&#xD;
                sideways with short, rapid movements. the computer calculates the accuracy and the&#xD;
                velocity of the eyes movements.&#xD;
&#xD;
             -  The participants fills a dizziness handicap inventory questionnaire. The&#xD;
                participants from the psoriatic group are recruited from the dermatology clinic.&#xD;
                The healthy group participants are members of the hospital staff and are recruited&#xD;
                from the hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>the participants are divided into 2 groups: psoriatic patients and healthy volunteers.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hearing test</measure>
    <time_frame>up to 2 weeks after recruitment. estimation time of the outcome is 10 minutes.</time_frame>
    <description>Determining the threshold of each measured tone in decibel units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hearing test</measure>
    <time_frame>up to 2 weeks after recruitment. estimation time of the outcome is 10 minutes.</time_frame>
    <description>Determining the speech threshold in decibel units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tympanometry</measure>
    <time_frame>up to 2 weeks after recruitment. estimation time of the outcome is 3 minutes.</time_frame>
    <description>Determining the type of tympanometry ( one out of the 3 possible options:A,B,C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Otoacoustic emission</measure>
    <time_frame>up to 2 weeks after recruitment. estimation time of the outcome is 3 minutes.</time_frame>
    <description>Determining existence or abscence of physiologic otoacoustic emissions in 500, 1000, 2000 Herts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Video head impulse test</measure>
    <time_frame>up to 2 weeks after recruitment. estimation time of the outcome is 10 minutes.</time_frame>
    <description>Measuring the velocity of eye movement compared to velocity of the head while the head is thrusted. The measured units are degrees/ seconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dizziness handicap inventory</measure>
    <time_frame>up to 2 weeks after recruitment. estimation time of the outcome is 5 minutes.</time_frame>
    <description>A questionnaire filled out by the participant, assesses subjectively the level of dizziness from which the patient suffers. Score varies between 0-100</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>psoriatic patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>psoriatic patients that are recruited from the dermatology clinic. This arm will undergo audiovestibular evaluation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers that are members of the hospital staff and will be recruited from the hospital. This arm will undergo audiovestibular evaluation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>audiovestibular function</intervention_name>
    <description>Hearing test- includes a pure tone audiometry, speech audiometry and discrimination level.&#xD;
tympanometry- Includes inserting headphones into the participants ears and computer calculation the compliance of the eardrum.&#xD;
otoacoustic emission: Includes headphones insertion and calculation of the inner ear audiological function.&#xD;
Video head impulse test.&#xD;
- Dizziness handicap inventory questionnaire. questionnaire filled by the participants provides a subjective data regarding the severity of the dizziness.</description>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>psoriatic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Psoriatic patients that are treated in our institute.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from cardiovascular diseases (peripheral vascular&#xD;
             disease,congestive heart failure, status post cerebrovascular accident).&#xD;
&#xD;
          -  Conditions that are harmful to the inner ear (chronic renal failure,history of noise&#xD;
             exposure, usage of ototoxic drugs, chronic otitis media, ear surgery in the past,&#xD;
             significant head trauma in the past, ear drum perforation).&#xD;
&#xD;
          -  participant that complains of vertigo/ dizziness/ unsteadiness.&#xD;
&#xD;
          -  Participant who is/ was suffering from known inner ear disease: meniere disease,&#xD;
             acoustic neurinoma, vestibular neuronitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miki Paker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>haemek medical center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miki Paker, MD</last_name>
    <phone>972526596552</phone>
    <email>miki_pa@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salim mazzaawi, MD</last_name>
    <phone>972544393994</phone>
    <email>salim_ma@clalit.org.il</email>
  </overall_contact_backup>
  <reference>
    <citation>Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007 Feb;143(2):239-42.</citation>
    <PMID>17310004</PMID>
  </reference>
  <reference>
    <citation>Halligan CS, Bauch CD, Brey RH, Achenbach SJ, Bamlet WR, McDonald TJ, Matteson EL. Hearing loss in rheumatoid arthritis. Laryngoscope. 2006 Nov;116(11):2044-9.</citation>
    <PMID>17075400</PMID>
  </reference>
  <reference>
    <citation>Bayazit YA, Yilmaz M, Gunduz B, Altinyay S, Kemaloglu YK, Onder M, Gurer MA. Distortion product otoacoustic emission findings in Beh√ßet's disease and rheumatoid arthritis. ORL J Otorhinolaryngol Relat Spec. 2007;69(4):233-8. Epub 2007 Apr 4.</citation>
    <PMID>17409782</PMID>
  </reference>
  <reference>
    <citation>Dagli M, Sivas Acar F, Karabulut H, Eryilmaz A, Erkol Inal E. Evaluation of hearing and cochlear function by DPOAE and audiometric tests in patients with ankylosing spondilitis. Rheumatol Int. 2007 Apr;27(6):511-6. Epub 2006 Nov 9.</citation>
    <PMID>17094003</PMID>
  </reference>
  <reference>
    <citation>Yen YC, Lin YS, Weng SF, Lai FJ. Risk of sudden sensorineural hearing loss in patients with psoriasis: a retrospective cohort study. Am J Clin Dermatol. 2015 Jun;16(3):213-20. doi: 10.1007/s40257-015-0117-9.</citation>
    <PMID>25687690</PMID>
  </reference>
  <reference>
    <citation>Vir D, Sharma P, Mahajan R, Dogra S, Bakshi J, Panda NK. Investigation of high-frequency hearing loss and outer hair cell function of the cochlea in patients with psoriasis: a case-control study. Clin Exp Dermatol. 2019 Jul;44(5):520-523. doi: 10.1111/ced.13805. Epub 2018 Oct 2.</citation>
    <PMID>30280411</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 3, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>Paker Miki</investigator_full_name>
    <investigator_title>principal investigator, Dr. Miki Paker</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The individual participant data will be collected in the principal investigator computer for a period of 7 years.&#xD;
The computer has a personal password and the computer if located inside a locked room.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

